1-ethyl-3-(3-[(4-oxopiperidin-1-yl)carbonyl]-1-benzothiophen-2-yl)urea | 1186019-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-3-(3-[(4-oxopiperidin-1-yl)carbonyl]-1-benzothiophen-2-yl)urea
• 英文别名: 1-ethyl-3-(3-(4-oxopiperidine-1-carbonyl)benzo[b]thiophen-2-yl)urea；1-ethyl-3-[3-(4-oxopiperidine-1-carbonyl)-1-benzothiophen-2-yl]urea
• CAS: 1186019-91-9
• 化学式: C₁₇H₁₉N₃O₃S
• 分子量: 345.422
• InChiKey: GLASKMUVUWBNGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-ethyl-3-(3-[(4-oxopiperidin-1-yl)carbonyl]-1-benzothiophen-2-yl)urea 、 spiro[6,7,8,9-tetrahydro-5H-pyrazolo[1,2-a]diazepine-2,3'-piperidine]-1,3-dione 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-[3-[4-(1,3-dioxospiro[6,7,8,9-tetrahydro-5H-pyrazolo[1,2-a]diazepine-2,3'-piperidine]-1'-yl)piperidine-1-carbonyl]-1-benzothiophen-2-yl]-3-ethylurea
  参考文献：
  名称：

  Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-pyrazolidinedione derivatives without quaternary chiral center were discovered by structure-based drug design and characterized as potent acetyl-CoA carboxylase (ACC) inhibitors. The high metabolic stability of the spiro-pyrazolo[1,2-a] pyridazine scaffold and enhancement of the activity by incorporation of a 7-methoxy group on the benzothiophene core successfully led to the identification of compound 4c as an orally bioavailable and highly potent ACC inhibitor. Oral administration of 4c significantly decreased the values of the respiratory quotient in rats, indicating the stimulation of fatty acid oxidation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.062
• 作为产物：
  描述：

  1-(2-aminobenzo[b]thiophene-3-carbonyl)piperidin-4-one 、 异氰酸乙酯 在 吡啶 作用下， 反应 8.0h， 以85%的产率得到1-ethyl-3-(3-[(4-oxopiperidin-1-yl)carbonyl]-1-benzothiophen-2-yl)urea
  参考文献：
  名称：

  ACETYL CoA CARBOXYLASE INHIBITORS

  摘要：

  本发明涉及乙酰辅酶A羧化酶（“ACC”）抑制化合物，其化学式如下 其中变量如本文所述定义。特别是，本发明涉及ACC1和/或ACC2抑制剂，包含这些化合物的物质、套件和制品，抑制ACC1和/或ACC2的方法，以及制造抑制剂的方法。

  公开号：

  US20090253725A1

文献信息

• Acetyl CoA carboxylase inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07981904B2

  公开（公告）日：2011-07-19

  The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.

  本发明涉及一种抑制乙酰辅酶A羧化酶（“ACC”）的化合物，其化学式为其中变量的定义如本文所述。特别地，本发明涉及ACC1和/或ACC2抑制剂、物质组成、包含这些化合物的工具箱和制品、抑制ACC1和/或ACC2的方法，以及制造这些抑制剂的方法。
• US7981904B2
  申请人：——

  公开号：US7981904B2

  公开（公告）日：2011-07-19
• ACETYL CoA CARBOXYLASE INHIBITORS
  申请人：Chang Edcon

  公开号：US20090253725A1

  公开（公告）日：2009-10-08

  The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.

  本发明涉及乙酰辅酶A羧化酶（“ACC”）抑制化合物，其化学式如下 其中变量如本文所述定义。特别是，本发明涉及ACC1和/或ACC2抑制剂，包含这些化合物的物质、套件和制品，抑制ACC1和/或ACC2的方法，以及制造抑制剂的方法。
• Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors
  作者：Makoto Kamata、Tohru Yamashita、Asato Kina、Michiko Tawada、Satoshi Endo、Atsushi Mizukami、Masako Sasaki、Akiyoshi Tani、Yoshihide Nakano、Yuuki Watanabe、Naoki Furuyama、Miyuki Funami、Nobuyuki Amano、Kohji Fukatsu

  DOI：10.1016/j.bmcl.2012.05.062

  日期：2012.7

  Spiro-pyrazolidinedione derivatives without quaternary chiral center were discovered by structure-based drug design and characterized as potent acetyl-CoA carboxylase (ACC) inhibitors. The high metabolic stability of the spiro-pyrazolo[1,2-a] pyridazine scaffold and enhancement of the activity by incorporation of a 7-methoxy group on the benzothiophene core successfully led to the identification of compound 4c as an orally bioavailable and highly potent ACC inhibitor. Oral administration of 4c significantly decreased the values of the respiratory quotient in rats, indicating the stimulation of fatty acid oxidation. (C) 2012 Elsevier Ltd. All rights reserved.